Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 796

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 796
---
, pursuant to which the Company agreed to pay Mr. Fernandez -McGoverna monthly retainer for her services of $ 18,000per month. For the year ended December 31, 2024, the Company recorded fees to Ms. Fernandez -McGovernof $ 54,316which is included in general and administrative expenses on the statement of operating and comprehensive loss. Note 13 Subsequent Events: Management has evaluated subsequent events that have occurred through the date these consolidated financial statements were issued. In January 2025, the Company completed the initial closing of $ 500,000of the previously announced $ 1million financing between the Company and an accredited investor under a securities purchase agreement dated December 4, 2024, with the approval of certain items in Company’s extraordinary general meeting on January 7, 2025. As of May 15, 2025, the conditions for the second tranche were not met and did not occur. On January 30, 2025, the Merger Agreement was amended such that it includes the right of the Company and Kadimastem to terminate the Merger Agreement if the Closing shall not have occurred on or before April 30, 2025, which outside date can be further extended by mutual agreement. Further, the amendment included an additional provision providing that any shareholder receiving common shares in excess of a 9.99% beneficial ownership limitation as a result of the Merger, shall instead be issued pre -fundedwarrants exercisable for a number of common shares in excess of the beneficial ownership limitation, at an exercise price equal to the par value of the common shares as of the Effective Time, which, in any event, shall be no less than CHF 0.0001per share. In addition, on May 5, 2025, the Merger Agreement was further amended to further extend the outside date to June 30, 2025. On March 27, 2025, the Company entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122Preferred Shares with a conversion price of $ 1.65per share, for aggregate gross proceeds of $ 2million. Pursuant to the terms of the March 2025 SPA, the investors may